Skip to main content

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.

Publication ,  Journal Article
McClay, JL; Adkins, DE; Aberg, K; Bukszár, J; Khachane, AN; Keefe, RSE; Perkins, DO; McEvoy, JP; Stroup, TS; Vann, RE; Beardsley, PM ...
Published in: Neuropsychopharmacology
February 2011

Neurocognitive deficits are a core feature of schizophrenia and, therefore, represent potentially critical outcome variables for assessing antipsychotic treatment response. We performed genome-wide association studies (GWAS) with 492K single nucleotide polymorphisms (SNPs) in a sample of 738 patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness study. Outcome variables consisted of a neurocognitive battery administered at multiple time points over an 18-month period, measuring processing speed, verbal memory, vigilance, reasoning, and working memory domains. Genetic mediation of improvements in each of these five domains plus a composite neurocognitive measure was assessed for each of five antipsychotics (olanzapine, perphenazine, quetiapine, risperidone, and ziprasidone). Six SNPs achieved genome-wide significance using a pre-specified threshold that ensures, on average, only 1 in 10 findings is a false discovery. These six SNPs were located within, or in close proximity to, genes EHF, SLC26A9, DRD2, GPR137B, CHST8, and IL1A. The more robust findings, that is those significant across multiple neurocognitive domains and having adjacent SNPs showing evidence for association, were rs286913 at the EHF gene (p-value 6.99 × 10(-8), q-value 0.034, mediating the effects of ziprasidone on vigilance), rs11240594 at SLC26A9 (p-value 1.4 × 10(-7), q-value 0.068, mediating the effects of olanzapine on processing speed), and rs11677416 at IL1A (p-value 6.67 × 10(-7), q-value 0.081, mediating the effects of olanzapine on working memory). This study has generated several novel candidate genes for antipsychotic response. However, our findings will require replication and functional validation. To facilitate replication efforts, we provide all GWAS p-values for download.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuropsychopharmacology

DOI

EISSN

1740-634X

Publication Date

February 2011

Volume

36

Issue

3

Start / End Page

616 / 626

Location

England

Related Subject Headings

  • Transcription Factors
  • Time Factors
  • Sulfate Transporters
  • Schizophrenia
  • Psychiatry
  • Polymorphism, Single Nucleotide
  • Pharmacogenetics
  • Neuropsychological Tests
  • Memory, Short-Term
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McClay, J. L., Adkins, D. E., Aberg, K., Bukszár, J., Khachane, A. N., Keefe, R. S. E., … van den Oord, E. J. C. G. (2011). Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology, 36(3), 616–626. https://doi.org/10.1038/npp.2010.193
McClay, Joseph L., Daniel E. Adkins, Karolina Aberg, Jozsef Bukszár, Amit N. Khachane, Richard S. E. Keefe, Diana O. Perkins, et al. “Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Neuropsychopharmacology 36, no. 3 (February 2011): 616–26. https://doi.org/10.1038/npp.2010.193.
McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RSE, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology. 2011 Feb;36(3):616–26.
McClay, Joseph L., et al. “Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Neuropsychopharmacology, vol. 36, no. 3, Feb. 2011, pp. 616–26. Pubmed, doi:10.1038/npp.2010.193.
McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RSE, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJCG. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology. 2011 Feb;36(3):616–626.

Published In

Neuropsychopharmacology

DOI

EISSN

1740-634X

Publication Date

February 2011

Volume

36

Issue

3

Start / End Page

616 / 626

Location

England

Related Subject Headings

  • Transcription Factors
  • Time Factors
  • Sulfate Transporters
  • Schizophrenia
  • Psychiatry
  • Polymorphism, Single Nucleotide
  • Pharmacogenetics
  • Neuropsychological Tests
  • Memory, Short-Term
  • Male